Liu Shen Wan inhibits influenza virus-induced secondary Staphylococcus aureus infection in vivo and in vitro

Zhao, Jin; Wang, Yutao; Huang, Xiaodong; Ma, Qiang; Song, Jian; Wu, Xiao Y.; Zhou, Hongxia; Weng, Yunceng; Yang, Zifeng; Wang, Xinhua

doi:10.1016/j.jep.2021.114066

Cited by 16 publications

(21 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies have shown that LS displayed an anti-inflammatory, anti-cancer, anti-viral, analgesic, and antibacterial activities in a variety of diseases. In treating influenza, LS capsule inhibited the virus replication and proliferation in vitro and ameliorated pneumonia damage in vivo via suppressing the TLR4/NF-lB signaling pathway (Ma et al, 2020a;Zhao et al, 2021). LS capsule also inhibited SARS-CoV-2 virus infection via regulating the activity of the NF-κB/MAPK signaling pathway in vitro (Ma et al, 2020b).…”

Section: Introductionmentioning

confidence: 99%

Liu Shen Capsule Alters Airway Microbiota Composition and Metabolite Profiles in Healthy Humans

Wang

Chen

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Alteration in airway microbiota composition and perturbations in microbe-metabolites interactions have been proposed as markers of many diseases. Liu Shen (LS) capsule, a traditional Chinese medicine, was proved as favorable in treating respiratory diseases. However, the effects of the LS capsule in terms of regulating human microorganisms and metabolite profiles are not well known. This study aimed to define and compare the respiratory microbiota composition and circulating and fecal metabolite profiles before and after LS capsule administration. A total of 30 healthy volunteers were recruited. The pharyngeal swab samples were collected for 16S rRNA gene sequencing. The serum and fecal samples were collected to analyze the non-targeted ultra-performance liquid chromatography–tandem mass spectrometry metabolomics. The airway microbial compositions were profoundly altered after LS capsule administration, as evidenced by increased microbial diversity and altered microbial taxa distribution. The increasing abundance of bacterial Bifidobacteria, and Lactobacillus characterized the after-administration groups, and the increasing of abundance bacterial Proteobacteria, Veillonella, Prevotella, Neisseria, and Actinomyces characterized the before-administration groups. Significant discriminations were observed in both serum and fecal metabolic profiles between the before- and after-administration groups. A total number of 134 and 71 significant HMDB taxonomic metabolites including glycerophospholipids, fatty acyls, and prenol lipids in the serum and fecal samples were identified respectively between the before- and after-administration groups. The integrated analysis showed that some altered airway microbiota phylum, such as Bacteroidetes and Proteobacteria, significantly correlated with metabolites in serum and fecal. Hence, our study reported the alternations in the composition and functions of the airway microbial community and the changes in circulating and fecal metabolite profiles after LS capsule administration in healthy humans, thus providing a novel insight into the mechanisms underlying the role of LS capsule treating and preventing related diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Liu Shen Capsule Alters Airway Microbiota Composition and Metabolite Profiles in Healthy Humans

Wang

Chen

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…2006; Zhao et al . 2021), the mRNA expression of adhesion genes during viral infection was determined in an EPS pre‐treatment study. As shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Similar results have shown in previous studies that the expression of CEACAM‐1, but not VCAM‐1, fibronectin or PAF‐r, on A549 cells was enhanced during influenza virus infection, as measured using both quantitative RT‐PCR and Western blotting methods (Zhao et al . 2021). However, the mechanisms underlying the CEACAM‐1 upregulation during influenza virus infection remain unclear.…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, secondary bacterial adherence assays were performed according to previously described methods using S. aureus (Zhao et al . 2021). As shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

“…2017; Zhao et al . 2021). However, whether or not EPS derived from OLL1073R‐1 affects secondary bacterial infection during influenza virus infection remains unclear.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Exopolysaccharides from Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 prevent influenza virus infection and attenuate secondary bacterial infection risk

Ishikawa

Kuno

Kohda

et al. 2022

Letters in Applied Microbiology

View full text Add to dashboard Cite

Significance and Impact of the Study: This study demonstrated that exopolysaccharides (EPS) derived from Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 prevent influenza virus infection to A549 cells in vitro. Moreover, the EPS reduced upregulated expression of CEACAM-1 (an adhesion molecule for bacterial adherence) on A549 cells resulting in reducing the bacterial adhesion to viral-infected cells. This attenuates the risk of secondary bacterial infection.

show abstract

Oral Liushen pill for patients with COVID‐19: A prospective randomized controlled trial

et al. 2023

View full text Add to dashboard Cite

Objective To analyze the e cacy and safety of Liushen Pill combined with basic treatment on patients with COVID-19.Methods One-hundred-eighty-one patients hospitalized with COVID-19, classi ed as asymptomatic, mild type, were randomly separated into the experimental (n=91) and control (n=90) groups. The control group was given placebo (Maizao decoction), while the experimental group was given Maizao decoction and Liushen pill, in addition to standard care. The negative conversion rate of nucleic acid (Day 7), hospital discharge rate (Day 8,10,14), symptom disappearance rate (Day 3, 5, 7), in ammatory cytokines and adverse events between the two groups were compared. ResultsThe negative viral conversion rate in the experimental group was signi cantly higher than that in the control group (48.35% vs 31.11%, P 0.05). Subgroup analysis showed a similar signi cant trend when the Ct value was ≤ 30 at baseline. After 10 days, the hospital discharge rate was signi cantly higher in the experimental than the control group (69.23% vs 53.33%, P 0.05). After 3 days of medication, the headache symptoms signi cantly disappeared in the experimental group (88.57%) compared to the control group (63.33%) (P 0.05). After 5 days, symptom disappearance rate of headache in the experimental group (97.14%) was still signi cantly higher than that in the control group (80.00%) (P 0.05), as was the symptom disappearance rate of cough (82.65% vs 58.93%, P 0.01). After treatment, the PCT level was signi cantly lower in the experimental than the control group (0.09±0.00 ng/L vs 0.14±0.05 ng/L) (P 0.05). There were no signi cant between-groups differences in clinical safety test indexes. ConclusionEarly intervention with Liushen Pill could improve the symptoms of cough and headache, and increase negative viral conversion and discharge rate.

show abstract

Liu Shen Wan inhibits influenza virus-induced secondary Staphylococcus aureus infection in vivo and in vitro

Cited by 16 publications

References 42 publications

Liu Shen Capsule Alters Airway Microbiota Composition and Metabolite Profiles in Healthy Humans

Liu Shen Capsule Alters Airway Microbiota Composition and Metabolite Profiles in Healthy Humans

Exopolysaccharides from Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 prevent influenza virus infection and attenuate secondary bacterial infection risk

Oral Liushen pill for patients with COVID‐19: A prospective randomized controlled trial

Contact Info

Product

Resources

About